Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 dose-escalation study in adults with Fabry disease
RBR-97trz9Phase 2Withdrawn
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
- Start
- Dec 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegunigalsidase alfa in Fabry disease (FD) (3 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Primary endpoints: Safety and Tolerability. Planned start Dec 2013; status: withdrawn.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on RBR-97trz9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-97trz9.